THE Generic Medicines Working Group (GMWG) has agreed to continue to work together to further develop strategies and measures supporting the generics and biosimilars sector, according to a communiqu from the 01 Dec 2016 meeting issued last week.
The four policy priorities being pursued by the GMWG relate to the work of the Pricing Policy, Supply and Viability sub-group, and the Uptake Drivers of Generic and Biosimilar Medicines sub-group.
The meeting also discussed the work being undertaken by the European Medicines Agency to promote transparency around clinical trial data.
Attendees included co-chairs Allan Tillack, chair of Generic and Biosimilar Medicines Association (GBMA) and Andrew Stuart, deputy secretary, Department of Health as well as representatives of the GBMA and the Pharmaceutical Benefits Division, Department of Health.
CLICK HERE for the communiqu.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Jan 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Jan 17
